(LYB) LyondellBasell Industries - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: NL0009434992
Stock:
Total Rating 33
Risk 79
Buy Signal -0.51
| Risk 5d forecast | |
|---|---|
| Volatility | 41.8% |
| Relative Tail Risk | -4.52% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.27 |
| Alpha | -31.41 |
| Character TTM | |
|---|---|
| Beta | 0.893 |
| Beta Downside | 2.048 |
| Drawdowns 3y | |
|---|---|
| Max DD | 55.35% |
| CAGR/Max DD | -0.17 |
EPS (Earnings per Share)
Revenue
Description: LYB LyondellBasell Industries
LyondellBasell Industries N.V. operates as a chemical company in the United States, Germany, Mexico, Italy, Poland, France, Japan, China, the Netherlands, and internationally. The company operates in six segments: Olefins and Polyolefins'Americas; Olefins and Polyolefins'Europe, Asia, International; Intermediates and Derivatives; Advanced Polymer Solutions; Refining; and Technology. It produces and markets olefins and co-products, such as ethylene, aromatics, propylene and butadiene; polyolefins; polyethylene; and polypropylene homopolymers and copolymers; and propylene oxide and derivatives; oxyfuels and related products; and intermediate chemicals, such as styrene monomer, acetyls, and ethylene oxide. The company also produces and markets compounding and solutions, including polypropylene compounds, engineered plastics, masterbatches, engineered composites, colors and powders, and advanced polymers, such as catalloy and polybutene-1; and refines heavy, high-sulfur crude oil and other crude oils, as well as refined products, including gasoline and distillates. In addition, it develops and licenses chemical and polyolefin process technologies; manufactures and sells polyolefin catalysts; and serves food packaging, home furnishings, automotive components, and paints and coatings applications. LyondellBasell Industries N.V. was incorporated in 2009 and is headquartered in Houston, Texas.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: -743.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 1.17m > 0.02 and ΔFCF/TA 117.1m > 1.0 |
| NWC/Revenue: -20.33% < 20% (prev 15.85%; Δ -36.18% < -1%) |
| CFO/TA 4.24m > 3% & CFO 2.67b > Net Income -743.0m |
| Net Debt (10.59b) to EBITDA (1.19b): 8.94 < 3 |
| Current Ratio: 0.00 > 1.5 & < 3 |
| Outstanding Shares: last quarter (322.0m) vs 12m ago -1.23% < -2% |
| Gross Margin: 9.00% > 18% (prev 0.13%; Δ 887.3% > 0.5%) |
| Asset Turnover: 168.7% > 50% (prev 98.15%; Δ 70.56% > 0%) |
| Interest Coverage Ratio: -0.40 > 6 (EBITDA TTM 1.19b / Interest Expense TTM 507.0m) |
Altman Z'' -15.00
| A: -9.73m (Total Current Assets 630.0 - Total Current Liabilities 6.13b) / Total Assets 630.0 |
| B: 10.8m (Retained Earnings 6.81b / Total Assets 630.0) |
| C: -0.01 (EBIT TTM -205.0m / Avg Total Assets 17.87b) |
| D: 0.18 (Book Value of Equity 3.93b / Total Liabilities 21.90b) |
| Altman-Z'' Score: -28.6m = D |
Beneish M
| DSRI: none (Receivables none/3.55b, Revenue 30.15b/35.08b) |
| GMI: 1.45 (GM 9.00% / 13.08%) |
| AQI: none (AQ_t none / AQ_t-1 none) |
| SGI: 0.86 (Revenue 30.15b / 35.08b) |
| TATA: -5.42m (NI -743.0m - CFO 2.67b) / TA 630.0) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of LYB shares?
As of February 25, 2026, the stock is trading at USD 58.32 with a total of 6,425,981 shares traded.
Over the past week, the price has changed by +4.18%, over one month by +14.67%, over three months by +32.27% and over the past year by -17.13%.
Over the past week, the price has changed by +4.18%, over one month by +14.67%, over three months by +32.27% and over the past year by -17.13%.
Is LYB a buy, sell or hold?
LyondellBasell Industries has received a consensus analysts rating of 3.27.
Therefor, it is recommend to hold LYB.
- StrongBuy: 5
- Buy: 1
- Hold: 13
- Sell: 1
- StrongSell: 2
What are the forecasts/targets for the LYB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 51.1 | -12.4% |
| Analysts Target Price | 51.1 | -12.4% |
LYB Fundamental Data Overview February 21, 2026
P/E Forward = 18.4162
P/S = 0.4714
P/B = 1.7495
P/EG = 1.3054
Revenue TTM = 30.15b USD
EBIT TTM = -205.0m USD
EBITDA TTM = 1.19b USD
Long Term Debt = 10.64b USD (from longTermDebt, two quarters ago)
Short Term Debt = 588.0m USD (from shortTermDebt, last quarter)
Debt = 14.04b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.59b USD (from netDebt column, last quarter)
Enterprise Value = 28.40b USD (17.81b + Debt 14.04b - CCE 3.45b)
Interest Coverage Ratio = -0.40 (Ebit TTM -205.0m / Interest Expense TTM 507.0m)
EV/FCF = 38.48x (Enterprise Value 28.40b / FCF TTM 738.0m)
FCF Yield = 2.60% (FCF TTM 738.0m / Enterprise Value 28.40b)
FCF Margin = 2.45% (FCF TTM 738.0m / Revenue TTM 30.15b)
Net Margin = -2.46% (Net Income TTM -743.0m / Revenue TTM 30.15b)
Gross Margin = 9.00% ((Revenue TTM 30.15b - Cost of Revenue TTM 27.44b) / Revenue TTM)
Gross Margin QoQ = 6.49% (prev 11.73%)
Tobins Q-Ratio = 45.1m (set to none) (Enterprise Value 28.40b / Total Assets 630.0)
Interest Expense / Debt = 0.76% (Interest Expense 107.0m / Debt 14.04b)
Taxrate = 21.0% (US default 21%)
NOPAT = -161.9m (EBIT -205.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.00 (Total Current Assets 630.0 / Total Current Liabilities 6.13b)
Debt / Equity = 1.39 (Debt 14.04b / totalStockholderEquity, last quarter 10.08b)
Debt / EBITDA = 8.94 (Net Debt 10.59b / EBITDA 1.19b)
Debt / FCF = 14.35 (Net Debt 10.59b / FCF TTM 738.0m)
Total Stockholder Equity = 11.20b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.16% (Net Income -743.0m / Total Assets 630.0)
RoE = -6.63% (Net Income TTM -743.0m / Total Stockholder Equity 11.20b)
RoCE = -0.94% (EBIT -205.0m / Capital Employed (Equity 11.20b + L.T.Debt 10.64b))
RoIC = -0.70% (negative operating profit) (NOPAT -161.9m / Invested Capital 23.21b)
WACC = 5.42% (E(17.81b)/V(31.85b) * Re(9.21%) + D(14.04b)/V(31.85b) * Rd(0.76%) * (1-Tc(0.21)))
Discount Rate = 9.21% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -0.62%
[DCF] Terminal Value 80.82% ; FCFF base≈1.08b ; Y1≈707.9m ; Y5≈323.0m
[DCF] Fair Price = N/A (negative equity: EV 10.29b - Net Debt 10.59b = -298.4m; debt exceeds intrinsic value)
EPS Correlation: -83.03 | EPS CAGR: -58.05% | SUE: -3.95 | # QB: 0
Revenue Correlation: -92.94 | Revenue CAGR: -15.20% | SUE: 0.26 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.19 | Chg7d=-0.387 | Chg30d=-0.417 | Revisions Net=-5 | Analysts=14
EPS current Year (2026-12-31): EPS=2.67 | Chg7d=+0.106 | Chg30d=-0.664 | Revisions Net=-6 | Growth EPS=+57.0% | Growth Revenue=-3.0%
EPS next Year (2027-12-31): EPS=3.82 | Chg7d=-0.758 | Chg30d=-1.005 | Revisions Net=-8 | Growth EPS=+43.2% | Growth Revenue=+0.5%
[Analyst] Revisions Ratio: -1.00 (0 Up / 5 Down within 30d for Next Quarter)
P/S = 0.4714
P/B = 1.7495
P/EG = 1.3054
Revenue TTM = 30.15b USD
EBIT TTM = -205.0m USD
EBITDA TTM = 1.19b USD
Long Term Debt = 10.64b USD (from longTermDebt, two quarters ago)
Short Term Debt = 588.0m USD (from shortTermDebt, last quarter)
Debt = 14.04b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.59b USD (from netDebt column, last quarter)
Enterprise Value = 28.40b USD (17.81b + Debt 14.04b - CCE 3.45b)
Interest Coverage Ratio = -0.40 (Ebit TTM -205.0m / Interest Expense TTM 507.0m)
EV/FCF = 38.48x (Enterprise Value 28.40b / FCF TTM 738.0m)
FCF Yield = 2.60% (FCF TTM 738.0m / Enterprise Value 28.40b)
FCF Margin = 2.45% (FCF TTM 738.0m / Revenue TTM 30.15b)
Net Margin = -2.46% (Net Income TTM -743.0m / Revenue TTM 30.15b)
Gross Margin = 9.00% ((Revenue TTM 30.15b - Cost of Revenue TTM 27.44b) / Revenue TTM)
Gross Margin QoQ = 6.49% (prev 11.73%)
Tobins Q-Ratio = 45.1m (set to none) (Enterprise Value 28.40b / Total Assets 630.0)
Interest Expense / Debt = 0.76% (Interest Expense 107.0m / Debt 14.04b)
Taxrate = 21.0% (US default 21%)
NOPAT = -161.9m (EBIT -205.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.00 (Total Current Assets 630.0 / Total Current Liabilities 6.13b)
Debt / Equity = 1.39 (Debt 14.04b / totalStockholderEquity, last quarter 10.08b)
Debt / EBITDA = 8.94 (Net Debt 10.59b / EBITDA 1.19b)
Debt / FCF = 14.35 (Net Debt 10.59b / FCF TTM 738.0m)
Total Stockholder Equity = 11.20b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.16% (Net Income -743.0m / Total Assets 630.0)
RoE = -6.63% (Net Income TTM -743.0m / Total Stockholder Equity 11.20b)
RoCE = -0.94% (EBIT -205.0m / Capital Employed (Equity 11.20b + L.T.Debt 10.64b))
RoIC = -0.70% (negative operating profit) (NOPAT -161.9m / Invested Capital 23.21b)
WACC = 5.42% (E(17.81b)/V(31.85b) * Re(9.21%) + D(14.04b)/V(31.85b) * Rd(0.76%) * (1-Tc(0.21)))
Discount Rate = 9.21% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -0.62%
[DCF] Terminal Value 80.82% ; FCFF base≈1.08b ; Y1≈707.9m ; Y5≈323.0m
[DCF] Fair Price = N/A (negative equity: EV 10.29b - Net Debt 10.59b = -298.4m; debt exceeds intrinsic value)
EPS Correlation: -83.03 | EPS CAGR: -58.05% | SUE: -3.95 | # QB: 0
Revenue Correlation: -92.94 | Revenue CAGR: -15.20% | SUE: 0.26 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.19 | Chg7d=-0.387 | Chg30d=-0.417 | Revisions Net=-5 | Analysts=14
EPS current Year (2026-12-31): EPS=2.67 | Chg7d=+0.106 | Chg30d=-0.664 | Revisions Net=-6 | Growth EPS=+57.0% | Growth Revenue=-3.0%
EPS next Year (2027-12-31): EPS=3.82 | Chg7d=-0.758 | Chg30d=-1.005 | Revisions Net=-8 | Growth EPS=+43.2% | Growth Revenue=+0.5%
[Analyst] Revisions Ratio: -1.00 (0 Up / 5 Down within 30d for Next Quarter)